HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Roivant Sciences (NASDAQ:ROIV) and maintained a price target of $18.
August 15, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $18.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Roivant Sciences. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100